AstraZeneca (NASDAQ: AZN) reported second-quarter 2026 results that delivered an earnings beat but fell short on revenue expectations, even as the company navigated mixed outcomes from key late-stage clinical trials. The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.63, surpassing the analyst consensus estimate of $2.48 by approximately 6%. However, quarterly revenue came in at $15.384 billion, missing the expected $15.459 billion. Despite the top-line miss, CEO Pascal Soriot reaffirmed the company’s $80 billion total revenue ambition for 2026, citing confidence in its pipeline despite recent setbacks.

The financial performance was driven by strong growth in the oncology portfolio, which accounted for 48% of product revenue and rose 16% year-over-year to $7.33 billion. Key contributors included Enhertu, which saw revenue jump 33% to $888 million, and Imfinzi, which grew 27% to $1.85 billion. Conversely, the cardiovascular, renal, and metabolism segment declined 18% at constant currency, with Farxiga revenue falling 16% to $1.804 billion. Respiratory and Immunology revenue increased 13% to $2.43 billion, while rare disease revenue climbed 9% to $2.49 billion, led by Ultomiris sales of $1.31 billion.

Financial Performance Metrics

Pipeline Developments and Trial Results

AstraZeneca shared high-level results from two significant Phase 3 trials. The ALXN1210-TMA-313 study of Ultomiris (ravulizumab) in patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplant (HSCT) did not achieve statistical significance for its primary endpoint of event-free survival through 26 weeks compared to placebo. However, the company noted a trend toward treatment benefit in adults and adolescents and is advancing regulatory filings for pediatric patients based on overall survival data showing 87.2% survival at 26 weeks.

In oncology, the CLARITY-Gastric01 trial of sonesitatug vedotin (Sone-Ve) for advanced gastric cancers demonstrated a statistically significant improvement in overall survival versus investigator’s choice of therapy. While Sone-Ve showed a trend toward improved progression-free survival, it did not reach statistical significance for that secondary endpoint. The drug was well-tolerated with no new safety signals identified.

What the Numbers Show

The divergence between the substantial EPS growth of 141.28% and the modest revenue increase of 6.41% highlights AstraZeneca’s focus on margin expansion and operational efficiency. While the revenue miss was narrow, the strength in high-growth oncology products like Enhertu and Imfinzi offset declines in mature assets such as Farxiga. The mixed clinical data presents a nuanced picture: while the Ultomiris setback in adults is a disappointment, the push for pediatric approval maintains a pathway for value realization. Similarly, Sone-Ve’s overall survival benefit supports its potential as a later-line gastric cancer treatment, despite missing the progression-free survival endpoint. These developments underscore the volatility inherent in late-stage development, yet management’s reiterated guidance suggests these individual setbacks do not derail the broader financial trajectory.

Pomerantz LLP is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following the failure of a key clinical trial. On July 9, 2026, Ionis disclosed that the Phase-3 CARDIO-TTRansform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with AstraZeneca, did not meet its primary endpoint. The primary endpoint measured the reduction of combined cardiovascular death and recurrent events. Following this disclosure, Ionis's stock price fell $20.19 per share, or 23.9%, to close at $64.27 per share on July 9, 2026.

The investigation concerns whether Ionis and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Pomerantz LLP is examining whether the company made materially false or misleading statements to investors prior to the disclosure. The Wainua CARDIO-TTRansform study was the largest trial in the ATTR cardiomyopathy population. AstraZeneca had previously positioned the treatment as a key contributor toward its stated "$80 billion 2030 ambition."

Investors who purchased IONS shares and suffered losses are encouraged to check their eligibility to recover losses. Pomerantz LLP advises affected investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The firm handles investigations on a contingency basis with no upfront costs. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as a premier firm in corporate, securities, and antitrust class litigation.